Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas Biopharma Holdings, Inc. on January 3, 2019, covering events occurring on December 31, 2018. The Company is a Delaware corporation and has elected to be treated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and personnel changes rather than financial performance metrics.
Material Changes
The primary material change reported is the appointment of a new Chief Financial Officer (CFO). On January 3, 2019, the Company announced the appointment of Keith Kucinski as CFO, effective January 2, 2019.
Management Commentary and Compensation Details
Mr. Kucinski entered into an employment agreement with the following terms:
- Base Salary: $250,000 annually.
- Annual Bonus: Target amount of up to 30% of base salary, contingent on performance targets.
- Equity Grant: Options to purchase 250,000 shares of common stock under the 2013 Equity Incentive Plan.
- Severance: In the event of termination "without cause" or resignation for "good reason," Mr. Kucinski is entitled to 12 months of base salary, 12 months of COBRA benefits, and acceleration of 50% of outstanding equity awards, subject to a release agreement.
Mr. Kucinski previously served as CFO of RemedyOne (2015-2018) and held senior finance roles at Par Pharmaceutical Companies and Barr Pharmaceuticals.
Investor Verification Checklist
- Verify the terms of the Employment Agreement attached as Exhibit 10.1.
- Review the press release dated January 3, 2019 (Exhibit 99.1) for additional context on the leadership transition.
- Confirm the impact of the new CFO appointment on the Company's strategic financial planning in subsequent filings.